Ticagrelor With Low-dose Versus Regular Aspirin in Patients With Acute Coronary Syndrome (ACS) at High-Risk for Ischemia After Percutaneous Coronary Intervention

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1220 participants.

Also called NCT04240834

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 1,220 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04240834
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT04240834. Randomized; single masking; primary purpose treatment. Start 2021-02-01 (actual); primary completion 2025-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Ticagrelor With Low-dose Versus Regular Aspirin in Patients With Acute Coronary Syndrome (ACS) at High-Risk for Ischemia After Percutaneous Coronary Intervention
Acronym
LD-ASPIRIN
Condition
Acute Coronary Syndrome
Condition
Interventional Cardiology
Intervention (Drug)
Aspirin
Intervention (Drug)
Ticagrelor
Lead sponsor
Fu Wai Hospital, Beijing, China (class: other)

Record details

Record id
cardio:ct-nct04240834
Content hash
0d2b802a785c31bcb1b6ffa10f5289439a8a4b406a6e732bcf234513f0b3a8df